Biosimilars Canada

What Biosimilars Canada does

Biosimilars Canada is a national industry association headquartered in Toronto that represents biosimilar drug manufacturers operating in the Canadian market. The organization is structured as a for-profit private entity with 1-10 employees and provides leadership training and advocacy services to its members, including named manufacturers such as Celltrion.

Its core function is regulatory and policy advocacy directed at Health Canada, specifically pushing for faster approval timelines for biosimilar medicines. The association operates against a backdrop of a reported 400%+ increase in biosimilar submissions to Health Canada between 2016 and 2025, which has produced a regulatory backlog the organization seeks to address on behalf of its members.

Biosimilars Canada derives revenue through its association model, most plausibly via member dues, sponsorships, and related fees from biosimilar manufacturers active in Canada. Beyond this core advocacy mandate, no product, technology platform, or proprietary offering is documented; the entity is best characterized as a trade-association function rather than a product-led business.

Name

Biosimilars Canada

Website

https://biosimilarscanada.ca

Company type

Private

Headcount range

1–10 employees

Short description

Biosimilars Canada is a Toronto-based national industry association representing biosimilar drug manufacturers in Canada. It provides advocacy and leadership training to members and pushes Health Canada for faster biosimilar drug approvals.

Ownership category

akta.pro rank

Product category

Pharmaceutical Industry Association

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Biosimilar Development & Clinical/Regulatory Services (comparability, trials, pharmacovigilance) (HLAAAHAJ)

akta.pro secondary industry

Biosimilar Commercialization & Market Access (pricing, tendering, interchangeability, distribution) (HLAAAHAL)

Keywords

• Biosimilar advocacy
• Regulatory advocacy
• Pharmaceutical industry association
• Healthcare policy advocacy
• Drug approval lobbying

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales

Core offering

Biosimilars Canada is a national industry association that represents biosimilar drug manufacturers in regulatory discussions with Health Canada. The organization advocates for faster approval and adoption of lower-cost biosimilar medications, working to reduce approval backlogs and position Canada as an attractive market for biosimilar investment. It provides collective representation for member companies in policy and regulatory forums.

Differentiator

Problem solved

Functional benefit

Products and services

• Regulatory Advocacy and Representation

Quantifiable outcome

• Faster biosimilar approvals can reduce healthcare costs by keeping expensive brand-name biologics off formulary for shorter periods

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators1 record

Recent moves2 records

Expansion highlights2 records

Direct peers

• Medicines for Europe: European trade association representing generic and biosimilar manufacturers, engaging the EMA and EU institutions on biosimilar regulation, interchangeability, and market access — a structurally analogous advocacy mandate.
• Biosimilars Council (AAM): US-focused biosimilars industry advocacy body under the Association for Accessible Medicines, performing a comparable regulatory and policy advocacy function for biosimilar manufacturers in front of the FDA and US policymakers.

Broad incumbents

• International Federation of Pharmaceutical Manufacturers & Associations (IFPMA): Global industry federation representing biopharmaceutical manufacturers, including biosimilar producers, on international policy, regulatory, and trade matters — broader in scope than Biosimilars Canada but overlapping on advocacy.
• Innovative Medicines Canada: Canadian association representing innovative pharmaceutical companies, often on the opposing side of biosimilar substitution policy debates; comparable as a national pharma advocacy body engaging Health Canada.
• Amgen (Biosimilars Division): Major originator and biosimilar sponsor with significant Canadian market presence; relevant as both a potential member of Biosimilars Canada-style associations and as a benchmark biosimilar manufacturer shaping the regulatory debate.

Regional players

• Korean Biosimilars Association: Industry group in South Korea, a leading biosimilar manufacturing hub, advocating for biosimilar sponsors with Korean regulators and on export-related policy.
• Generic and Biosimilar Medicines Association (GBMA Australia): Australian industry association for generic and biosimilar medicines, performing an analogous regulatory-advocacy role in front of the TGA and Australian policymakers for biosimilar manufacturers.

Others

• Celltrion: A leading South Korean biosimilar manufacturer cited as a member in Biosimilars Canada's customer segment; relevant as a downstream stakeholder rather than a competitor, illustrating the type of sponsor the association serves.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat2 records

Key risks4 records

Key highlights3 records

Customer concentration

• Xx.com/cdnbiosimilars
• Facebookfacebook.com/biosimilarscanada
• LinkedInlinkedin.com/company/biosimilars-canada

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biosimilars Canada